Nusatama Berkah says IPO proceeds use reaches IDR 66.00 billion, IDR 532.40 million remains
Bitget2026/10/08 12:10PT Nusatama Berkah disclosed use of IPO proceeds from its Feb. 9, 2022 listing, raising IDR 70 billion with net proceeds of IDR 66.53 billion. As of June 30, 2026, realized use totaled IDR 66.00 billion, leaving IDR 532,397,200 unspent. Most funds were allocated to working capital at IDR 58.02 billion, equal to 87.21% of net proceeds. Machine purchases reached IDR 3.47 billion, below the IDR 4.01 billion plan; production-area expansion used IDR 4.50 billion. Remaining funds were placed in a Bank Permata demand deposit for three months at 2.5% interest. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Nusatama Berkah Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32164906) on October 08, 2026, and is solely responsible for the information contained therein.
- PT Nusatama Berkah disclosed use of IPO proceeds from its Feb. 9, 2022 listing, raising IDR 70 billion with net proceeds of IDR 66.53 billion.
- As of June 30, 2026, realized use totaled IDR 66.00 billion, leaving IDR 532,397,200 unspent.
- Most funds were allocated to working capital at IDR 58.02 billion, equal to 87.21% of net proceeds.
- Machine purchases reached IDR 3.47 billion, below the IDR 4.01 billion plan; production-area expansion used IDR 4.50 billion.
- Remaining funds were placed in a Bank Permata demand deposit for three months at 2.5% interest.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
